Limited value for pap tests in endometrial cancer recurrence

Limited value for pap tests in endometrial cancer recurrence
For women who have undergone a hysterectomy for endometrial cancer, abnormal Papanicolaou test results do not aid in diagnosing recurrent disease, according to a study published in the January issue of Obstetrics & Gynecology.

(HealthDay)—For women who have undergone a hysterectomy for endometrial cancer, abnormal Papanicolaou (Pap) test results do not aid in diagnosing recurrent disease, according to a study published in the January issue of Obstetrics & Gynecology.

Akiva P. Novetsky, M.D., from the Washington University School of Medicine and Siteman Center in St. Louis, and colleagues analyzed data from 433 women who underwent a for endometrial cancer between 2006 and 2010 and had at least one postoperative , with a total of 2,378 Pap tests.

The researchers found that 13 percent of women had at least one abnormal cytology result, representing 3 percent of all Pap tests. On the basis of isolated abnormal cytology, no recurrent endometrial cancers were diagnosed. For women with atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion Pap test results, there were no cases of recurrent cancer diagnosed. Abnormal cytology was significantly associated with previous postoperative radiation therapy, in multivariable analysis. For detecting a local recurrence, the sensitivity, specificity, and positive and negative predictive values of an abnormal Pap test result were 40, 87.9, 7.3, and 98.4 percent, respectively.

"Our study supports previous studies demonstrating the significant limitation of Pap tests in diagnosing recurrent endometrial cancer," the authors write. "We found no cases of salvageable local recurrence diagnosed after abnormal cytology in the absence of patient symptoms or physical examination findings."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Study urges three-year gap in cervical cancer test

May 18, 2011

Healthy women over 30 who test negative for human papillomaviruses (HPV) may be able to safely extend the period between gynecological exams from every year to three years, said a US study Wednesday.

HPV vaccine reduces abnormal pap test results

Mar 10, 2008

In testing GARDASIL reduced abnormal Pap test results by 43 percent compared to women not given the vaccine, according new research. The findings show the approved anti-HPV agent appears to prevent the development of cell ...

Recommended for you

Ob-gyn guidance issued for young cancer patient concerns

Jul 25, 2014

(HealthDay)—Young cancer patients and survivors may have gynecologic concerns, which should be managed before, during, and after treatment, according to a Committee Opinion published in the August issue ...

Common blood thinner for pregnant women proven ineffective

Jul 24, 2014

It's a daily injection to the belly for pregnant women at risk of developing blood clots and it's ineffective, according to a clinical trial led by researchers at The Ottawa Hospital and published today by the prestigious ...

Improving life before it begins

Jul 22, 2014

A group of Mexican specialists in fetal medicine have successfully performed over 200 surgeries on unborn babies, inside the womb of the mother. Doctors, grouped under the signature Fetal Medicine Mexico, ...

User comments